- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '95860'
    - '95861'
    - '95863'
    - '95864'
    loinc:
    - 33747-0
  conditions:
    any_of:
    - dx_in_value_set: vs_peripheral_neuropathy_2025_09
    - dx_in_value_set: vs_myopathy_suspected_2025_09
    - dx_in_value_set: vs_motor_neuron_disease_2025_09
    all_of:
    - age_gte: 18
    - has_flag: progressive_weakness
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: emg_within_6_months
  logic:
    outcome: PA_REQUIRED
    note: EMG/NCS for evaluation of suspected neuromuscular disorders
  precedence: 85
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_3fbbe8063001
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '20206'
    - '20225'
    loinc:
    - 33747-0
    - 26825-8
  conditions:
    any_of:
    - dx_in_value_set: vs_inflammatory_myopathy_2025_09
    - dx_in_value_set: vs_muscular_dystrophy_2025_09
    all_of:
    - age_gte: 18
    - has_flag: elevated_ck_levels
    - has_flag: abnormal_emg
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: bleeding_disorder
    - has_flag: anticoagulation_therapy
  logic:
    outcome: PA_REQUIRED
    note: Muscle biopsy for suspected inflammatory myopathy or muscular dystrophy
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_7f1ddcfc5130
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    j_codes:
    - J1568
    - J7799
    cpt:
    - '96365'
    - '96366'
  conditions:
    any_of:
    - dx_in_value_set: vs_myasthenia_gravis_2025_09
    - dx_in_value_set: vs_lambert_eaton_syndrome_2025_09
    all_of:
    - age_gte: 18
    - has_flag: confirmed_nmj_disorder
    - has_flag: myasthenic_crisis_or_severe_symptoms
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: cardiovascular_instability
    - has_flag: active_infection
  logic:
    outcome: PA_REQUIRED
    note: IVIG or plasma exchange for myasthenic crisis or severe neuromuscular junction
      disorders
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_634fc916195f
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    ndc:
    - 0078-0429
    - 0173-0830
    j_codes:
    - J7799
  conditions:
    any_of:
    - dx_in_value_set: vs_als_2025_09
    - dx_in_value_set: vs_motor_neuron_disease_2025_09
    all_of:
    - age_gte: 18
    - has_flag: confirmed_als_diagnosis
    - has_flag: progressive_motor_decline
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: end_stage_disease
    - has_flag: contraindication_to_therapy
  logic:
    outcome: PA_REQUIRED
    note: Disease-modifying therapy for ALS (riluzole, edaravone)
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_7e5dca9ae5cc
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '81479'
    - '81408'
    - '81406'
  conditions:
    any_of:
    - dx_in_value_set: vs_hereditary_neuropathy_2025_09
    - dx_in_value_set: vs_muscular_dystrophy_2025_09
    - dx_in_value_set: vs_spinal_muscular_atrophy_2025_09
    all_of:
    - age_gte: 18
    - has_flag: family_history_neuromuscular
    - has_flag: clinical_suspicion_genetic
    - has_flag: specialist_evaluation
    none_of: []
  logic:
    outcome: PA_REQUIRED
    note: Genetic testing for suspected hereditary neuromuscular disorders
  precedence: 85
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_7d435aeed136
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    j_codes:
    - J9999
    ndc:
    - 0078-0659
  conditions:
    any_of:
    - dx_in_value_set: vs_spinal_muscular_atrophy_2025_09
    - dx_in_value_set: vs_duchenne_muscular_dystrophy_2025_09
    all_of:
    - age_gte: 6
    - has_flag: confirmed_genetic_diagnosis
    - has_flag: ambulatory_or_sitting
    - has_flag: specialist_evaluation
    none_of:
    - has_flag: advanced_respiratory_failure
    - has_flag: contraindication_to_therapy
  logic:
    outcome: PA_REQUIRED
    note: Gene therapy or antisense oligonucleotides for genetic neuromuscular disorders
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_neurology_neuromuscular_2025.pdf
    last_verified_at: '2025-09-11'
    last_updated: '2025-09-11'
  id: rule_3550498b3997
